Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Kentuckiana Cancer Institute

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: Gemcitabine; Drug: Iscar Quercus

Study type: Interventional

Funder types: Other

Identifiers

NCT00283478

Mistletoe

1056757

Details and patient eligibility

About

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Full description

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
• Karnofsky score 60% or greater
• patients who will be treated with Gemcitabine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)